Sustiva (Efavirenz)

Antiviral effect of Sustiva (Generic) is due to the ability of efavirenz to selectively inhibit HIV-1 reverse transcriptase. Noncompetitive inhibition is dominant.  Efavirenz does not inhibit the synthesis of cellular DNA polymerases and HIV-2 transcriptase in humans.
The adsorption and time to reach the maximum concentration of Sustiva (Generic) in the blood plasma in HIV infected and in healthy people almost coincide. After a week, stable concentrations of this substance are recorded in the blood plasma.
The every day portion dictates the greatest fixation and an opportunity to achieve it. It is noticed that when taking pills with greasy sustenances, the centralization of efavirenz in the body stayed steady more. The level of authoritative of efavirenz to plasma proteins, for the most part egg whites, is very high. The convergence of the bound substance in plasma is around multiple times higher than the substance of its free portions
Sustiva (Generic) easily penetrates into the cerebrospinal fluid and is metabolized in the liver and blood plasma.
Also, the time of excretion from the body increases with severe liver dysfunctions. Sustiva (Generic) is excreted in the urine and feces.
Contraindications for using Sustiva (Generic):
Liver failure;
simultaneous use of ergot alkaloids (for example, dihydroergotamine, ergotamine, ergonovina, methylergonovina), triazolam, pimozide, midazolam, bepridil, cisapride, astemizole, terfenadine;
Simultaneous use of drugs;
Hypersensitivity to any component of the drug.
Instructions of using Sustiva (Generic)
Sustiva (Generic) should be taken orally, preferably at bedtime and on an empty stomach (since it may increase the frequency of side effects when taken during meals). The drug should be used in combination with other antiretroviral medicine.